Project 26

Improvement and risk modeling in the prevention of sudden cardiac death

Heart failure (HF) remains an important issue in cardiology because of its high mortality and morbidity. Sudden cardiac death is responsible for up to 50% of the reported mortality. The implantable defibrillator (ICD) has proven to be effective in reducing arrhythmic death in selected patients with ischemic or nonischemic cardiomyopathy and reduced left ventricular function. Despite the efficacy in terminating ventricular arrhythmias, there is an on-going debate on further risk stratification of patients who will benefit most from ICD implantation. The benefit of the ICD is attenuated by the presence of comorbidities. Identification of those patients at high risk for mortality who may not derive benefit from ICD implantation is important for optimal patient selection of this therapy. Erasmus MC has a cooperation with the University Hospital Basel and Seattle University for further development of risk estimation models in primary prevention of sudden death for better patient identification.

Next to risk modeling and clinical aspects of patients at risk for sudden death, efforts are made to incorporate patient-reported outcomes in clinical practice and decision-making. Erasmus MC has a cooperation with Tilburg University and University of South-Denmark Odense for research focusing on patient-reported outcomes. In addition, Erasmus MC has played a role in the development of new innovative technologies in the prevention of sudden death, like implementation of remote monitoring and the development of a subcutaneous defibrillator.

Principal InvestigatorDAMJ Theuns
Co-InvestigatorsMGM Hunink, SS Pedersen (Odense), BA Schaer (Basel)
PhD candidatesB van Veen (Odense), SDA Valk